Assay News and Research

RSS

Preliminary Mayo Clinic results from convalescent plasma in 35,322 patients

A new study published on the preprint server bioRxiv* in August 2020 reports the preliminary results of the US Expanded Access Program (EAP) for CP. The EAP aimed to facilitate access to CP as well as to evaluate the safety of this therapy. However, the current study reports the results of an initial assessment of this agent.

14 Aug 2020

Genomic analysis finds link between antibiotic resistance and heavy metal contamination

Antibiotic resistance is an increasing health problem, but new research suggests it is not only caused by the overuse of antibiotics. It's also caused by pollution.

13 Aug 2020

Membrane nanoparticles acts as a bait to trap SARS-CoV-2

In an exciting new bioRxiv preprint research paper, Chinese researchers describe the development of membrane nanoparticles from ACE2-rich cells with a potent capacity to block the adherence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

13 Aug 2020

Scientists identify genetic link to predict treatment response in patients with aggressive blood cancer

A Singapore team led by clinician-scientists and researchers from the National Cancer Centre Singapore (NCCS) discovered a genetic link to better predict treatment response for relapsed/refractory patients with natural- killer T-cell lymphoma (NKTCL), a highly aggressive form of blood cancer.

13 Aug 2020

Promega introduces new serological antibody test for COVID-19

Promega Corporation today announced the launch of its new serological antibody test for COVID-19 to detect the presence of antibodies against the SARS-CoV-2 virus.

From Promega Corporation 13 Aug 2020

A triplex SARS-CoV-2 assay based on nanopore sequencing is accurate, rapid and scalable

A novel breakthrough by a research group from Oxford Nanopore Technologies is a rapid way of testing and screening large numbers of samples for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

12 Aug 2020

Machine learning helps detect new potential drugs to treat COVID-19

Scientists at the University of California, Riverside, have used machine learning to identify hundreds of new potential drugs that could help treat COVID-19, the disease caused by the novel coronavirus, or SARS-CoV-2.

12 Aug 2020

Researchers develop novel approach for utilizing 4D-printing of arrays to accelerate drug testing

Investigators at Rutgers Cancer Institute of New Jersey have developed a novel approach for utilizing 4-dimensional (4D) printing of arrays that transform from cell-culture inserts into histological cassettes that hold patient tissue samples for rapid programmable drug testing.

12 Aug 2020

New technology could serve as more reliable model of amyotrophic lateral sclerosis

A new study published today demonstrates that a technology developed at the University of Central Florida could serve as a more reliable clinically-based model of amyotrophic lateral sclerosis (ALS) and a better screening tool for novel therapies than currently use preclinical models.

12 Aug 2020

1st human data for Sinovac's SARS-CoV-2 CoronaVac vaccine is out

A group of Chinese researchers recently conducted a phase 2 clinical trial to further evaluate the immunogenicity and safety of SARS-CoV-2 inactivated vaccine known as CoronaVac. The results are currently available on the medRxiv preprint server and demonstrate that the vaccine is well tolerated and without any notable dose-related safety concerns, which opens the door for phase 3 clinical trial.

11 Aug 2020

Inhaled delivery of a potent neutralizing nanobody effective against SARS-CoV-2

A recent study by researchers from China, available on the bioRxiv preprint server, shows how stable neutralizing nanobody Nb11-59 might be a promising prophylactic and therapeutic molecule against coronavirus disease (COVID-19) – especially if administered via the inhalatory route.

11 Aug 2020

Research looks at how long SARS-CoV-2 antibodies last

A new study by researchers at the Fred Hutchinson Cancer Research Center and the University of Washington and published on the preprint server medRxiv* in August 2020 deals with the changes in neutralizing antibodies in the following months.

11 Aug 2020

CRISPR-based COVID-19 surveillance

A recent US study available on the medRxiv preprint server supports the use of self-collected oropharyngeal swabs, together with CRISPR- and PCR-based diagnostic assays, as rapid, feasible and reliable approach for the surveillance of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in university students and other asymptomatic individuals

10 Aug 2020

COVID-19 patient with repeatedly undetectable SARS-CoV-2 antibodies

A recent case study published in the Journal of Applied Laboratory Medicine in August 2020 illustrates this with its finding of persistent seronegativity in a patient confirmed to be SARS-CoV-2 positive.

10 Aug 2020

FDA approves first companion diagnostic that uses liquid biopsy and NGS technology

Today, the U.S. Food and Drug Administration approved the first liquid biopsy companion diagnostic that also uses next-generation sequencing (NGS) technology to identify patients with specific types of mutations of the epidermal growth factor receptor (EGFR) gene in a deadly form of metastatic non-small cell lung cancer (NSCLC).

7 Aug 2020

Study: Drinking honeysuckle decoction accelerates the negative conversion of COVID-19 patients

In a new study in Cell Discovery, Chen-Yu Zhang's group at Nanjing University and two other groups from Wuhan Institute of Virology and the Second Hospital of Nanjing present a novel finding that absorbed miRNA MIR2911 in honeysuckle decoction (HD) can directly target SARS-CoV-2 genes and inhibit viral replication. Drinking of HD accelerate the negative conversion of COVID-19 patients.

7 Aug 2020

Vela Diagnostics' coronavirus PCR test receives Emergency Use Authorization from FDA

Vela Diagnostics announced that the manual version of its coronavirus PCR test has obtained Emergency Use Authorization from the U.S. Food and Drug Administration.

6 Aug 2020

Fujirebio announces launch of clinical testing for new SARS-CoV-2 Antigen assay

Fujirebio Diagnostics, Inc., a consolidated subsidiary of H.U. Group Holdings, Inc, announced today the initiation of clinical testing needed for the submission of its new SARS-CoV-2 Antigen assay for EUA (Emergency Use Authorization) from the U.S. Food and Drug Administration.

6 Aug 2020

Sanford Burnham Prebys receives NIH grant to identify new therapies for mental disorders

Sanford Burnham Prebys Medical Discovery Institute has been awarded a $4.5 million grant from the National Institutes of Health (NIH) to identify new therapies for mental health disorders.

6 Aug 2020

Fast, cheap and easy COVID-19 test from Yale

As a result, a new study by Yale University researchers and published on the preprint server medRxiv in August 2020 shows that a new saliva test named SalivaDirect simplifies the test approach, avoids invasive samples collection, and the need for trained personnel to collect specimens.

6 Aug 2020

Assay News and Research

Preliminary Mayo Clinic results from convalescent plasma in 35,322 patients

Genomic analysis finds link between antibiotic resistance and heavy metal contamination

Membrane nanoparticles acts as a bait to trap SARS-CoV-2

Scientists identify genetic link to predict treatment response in patients with aggressive blood cancer

Promega introduces new serological antibody test for COVID-19

A triplex SARS-CoV-2 assay based on nanopore sequencing is accurate, rapid and scalable

Machine learning helps detect new potential drugs to treat COVID-19

Researchers develop novel approach for utilizing 4D-printing of arrays to accelerate drug testing

New technology could serve as more reliable model of amyotrophic lateral sclerosis

1st human data for Sinovac's SARS-CoV-2 CoronaVac vaccine is out

Inhaled delivery of a potent neutralizing nanobody effective against SARS-CoV-2

Research looks at how long SARS-CoV-2 antibodies last

CRISPR-based COVID-19 surveillance

COVID-19 patient with repeatedly undetectable SARS-CoV-2 antibodies

FDA approves first companion diagnostic that uses liquid biopsy and NGS technology

Study: Drinking honeysuckle decoction accelerates the negative conversion of COVID-19 patients

Vela Diagnostics' coronavirus PCR test receives Emergency Use Authorization from FDA

Fujirebio announces launch of clinical testing for new SARS-CoV-2 Antigen assay

Sanford Burnham Prebys receives NIH grant to identify new therapies for mental disorders

Fast, cheap and easy COVID-19 test from Yale

Industry Focus eBook - Neurology/Neuroscience - 2nd edition eBook

How Omics Technologies Are Transforming Biological Research and Drug Discovery

How microplastics and bacteria interact to drive antibiotic resistance

Single-cell proteomics: Revealing proteome diversity from cellular heterogeneity to non-canonical biology

Latest News